Antiretroviral treatment of adult HIV infection: 2014 Recommendations of the International Antiviral Society-USA panel

JAMA

Volumn 312, Issue 4, 2014, Pages 410-425

  Günthard, Huldrych F ^a   Aberg, Judith A ^b   Eron, Joseph J ^c   Hoy, Jennifer F ^d   Telenti, Amalio ^e   Benson, Constance A ^f   Burger, David M ^g   Cahn, Pedro ^h   Gallant, Joel E ⁱ   Glesby, Marshall J ^j   Reiss, Peter ^k   Saag, Michael S ^l   Thomas, David L ^m   Jacobsen, Donna M ⁿ   Volberding, Paul A ^o  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d MONASH UNIVERSITY   (Australia)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSIDAD DE BUENOS AIRES   (Argentina)

ⁱ Southwest CARE Center   (United States)

^j WEILL CORNELL MEDICAL COLLEGE   (United States)

^k UNIVERSITY OF AMSTERDAM   (Netherlands)

^l UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^m JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ International Antiviral Society USA   (United States)

^o UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR; COBICISTAT; COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; DARUNAVIR; DOLUTEGRAVIR; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ELVITEGRAVIR; EMTRICITABINE; EMTRICITABINE PLUS RILPIVIRINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ENTECAVIR; ETRAVIRINE; LAMIVUDINE PLUS LOPINAVIR PLUS RITONAVIR; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; MARAVIROC; RALTEGRAVIR; RIFAMPICIN; RILPIVIRINE; RITONAVIR; TENOFOVIR; TIPRANAVIR;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; BONE DENSITY; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CHOLELITHIASIS; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG COST; DRUG MECHANISM; DRUG MONITORING; EARLY INTERVENTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL SOCIETY; MEDICATION COMPLIANCE; MIXED INFECTION; MORTALITY; MULTIDRUG RESISTANCE; NEPHROLITHIASIS; PATIENT MONITORING; PRACTICE GUIDELINE; PREGNANT WOMAN; PRIORITY JOURNAL; RASH; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; THERAPY DELAY; TIME TO TREATMENT; TUBERCULOSIS; UNITED STATES; VIRAL CLEARANCE; VIRUS TRANSMISSION;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG COSTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; TREATMENT FAILURE;

EID: 84904568743     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.8722     Document Type: Review

References (173)

1. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012;308(4):387-402.
2. Cohen MS, Chen YQ, McCauley M, et al HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493-505.
3. Tanser F, Bärnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science. 2013;339(6122):966-971.
4. Rodger A, Bruun T, Cambiano V, et al. HIV transmission risk through condomless sex if HIV+ partner on suppressive ART: PARTNER study [Abstract 153LB]. Top Antivir Med. 2014;22(e-1):24-25.
5. Rodger AJ, Lodwick R, Schechter M, et al INSIGHT SMART, ESPRIT Study Groups. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS. 2013;27(6):973-979.
6. Sáez-Cirión A, Bacchus C, Hocqueloux L, et al; ANRS VISCONTI Study Group. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 2013;9(3):e1003211.
7. Persaud D, Gay H, Ziemniak C, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med. 2013;369(19):1828-1835.
8. Canadian Task Force on the Periodic Health Examination. The Periodic Health Examination. Can Med Assoc J. 1979;121(9):1193-1254.
9. Wada N, Jacobson LP, Cohen M, French A, Phair J, Muñoz A. Cause-specific mortality among HIV-infected individuals, by CD4(+) cell count at HAART initiation, compared with HIV-uninfected individuals. AIDS. 2014;28(2):257-265.
10. Mocroft A, Furrer HJ, Miro JM, et al; Opportunistic Infections Working Group on behalf of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCOORD. The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era. Clin Infect Dis. 2013;57(7):1038-1047.
11. Cheung C, Ding E, Zhu J, et al. Expansion of ART and progressive declines in all-cause mortality in British Columbia, Canada [Poster 559]. Top Antivir Med. 2014;22(e-1):271-272.
12. Grinsztejn B, Hosseinipour MC, Ribaudo HJ, et al; HPTN 052-ACTG Study Team. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis. 2014;14(4):281-290.
13. Koenig SP, Bang H, Severe P, et al. Cost-effectiveness of early versus standard antiretroviral therapy in HIV-infected adults in Haiti. PLoS Med. 2011;8(9):e1001095.
14. Walensky RP, Sax PE, Nakamura YM, et al. Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med. 2013;158(2):84-92.
15. Kovari H, Sabin CA, Ledergerber B, et al. Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study. Clin Infect Dis. 2013;56(6):870-879.
16. World Health Organization (WHO). March 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. http://apps.who.int/iris/bitstream/10665/104264/1/9789241506830-eng.pdf. Accessed April 3, 2014.
17. Chun TW, Shawn Justement J, Murray D, et al. Effect of antiretroviral therapy on HIV reservoirs in elite controllers. J Infect Dis. 2013;208(9):1443-1447.
18. Hatano H, Yukl SA, Ferre AL, et al. Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers. PLoS Pathog. 2013;9(10):e1003691.
19. Boufassa F, Lechenadec J, Meyer L, et al; ANRS CO18 HIV Controllers Cohort; Cascade Collaboration in Eurocoord; SCOPE Cohort; International HIV Controllers Study. Blunted response to combination antiretroviral therapy in HIV elite controllers: an international HIV controller collaboration. PLoS One. 2014;9(1):e85516.
20. Wyl Vv, Gianella S, Fischer M, et al; Swiss HIV Cohort Study-SHCS. Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption. PLoS One. 2011;6(11):e27463.
21. Hocqueloux L, Avettand-Fènoël V, Jacquot S, et al; AC32 (Coordinated Action on HIV Reservoirs) of the Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS). Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. J Antimicrob Chemother. 2013;68(5):1169-1178.
22. Grijsen ML, Steingrover R, Wit FWNM, et al Primo-SHM Study Group. No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial. PLoS Med. 2012;9(3):e1001196.
23. Le T,Wright EJ, Smith DM, et al. Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med. 2013;368(3):218-230.
24. Chen J, Han X, An M, et al. Immunological and virological benefits resulted from short-course treatment during primary HIV infection: ameta-analysis. PLoS One. 2013;8(12):e82461.
25. Vinikoor MJ, Cope A, Gay CL, et al. Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activation. J Acquir Immune Defic Syndr. 2013;62(5):505-508.
26. Archin NM, Vaidya NK, Kuruc JD, et al. Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci U S A. 2012;109(24):9523-9528.
27. Rieder P, Joos B, von Wyl V, et al Swiss HIV Cohort Study. HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men. AIDS. 2010;24(8):1177-1183.
28. Jarvis JN, Bicanic T, Loyse A, et al. Determinants of mortality in a combined cohort of 501 patients with HIV-associated cryptococcal meningitis: implications for improving outcomes. Clin Infect Dis. 2014;58(5):736-745.
29. Bisson GP, Molefi M, Bellamy S, et al. Early versus delayed antiretroviral therapy and cerebrospinal fluid fungal clearance in adults with HIV and cryptococcal meningitis. Clin Infect Dis. 2013;56(8):1165-1173.
30. Njei B, Kongnyuy EJ, Kumar S, Okwen MP, Sankar MJ, Mbuagbaw L. Optimal timing for antiretroviral therapy initiation in patients with HIV infection and concurrent cryptococcal meningitis. Cochrane Database Syst Rev. 2013;2:CD009012.
31. Boulware DR,Meya DB, Muzoora C, et al; for the COAT Trial Team. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med. 2014;370(26):2487-2498.
32. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(3):291-322.
33. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001;344(11):824-831. (Pubitemid 32222162)
34. Schackman BR, Freedberg KA,Weinstein MC, et al. Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. Arch Intern Med. 2002;162(21):2478-2486. (Pubitemid 35340465)
35. Mauskopf J, Kitahata M, Kauf T, Richter A, Tolson J. HIV antiretroviral treatment: early versus later. J Acquir Immune Defic Syndr. 2005;39(5):562-569. (Pubitemid 41098471)
36. Chen RY, Accortt NA, Westfall AO, et al. Distribution of health care expenditures for HIV-infected patients. Clin Infect Dis. 2006;42(7):1003-1010.
37. Walmsley SL, Antela A, Clumeck N, et al SINGLE Investigators. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807-1818.
38. Raffi F, Rachlis A, Stellbrink HJ, et al; SPRING-2 Study Group. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381(9868):735-743.
39. Raffi F, Jaeger H, Quiros-Roldan E, et al; extended SPRING-2 Study Group. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013;13(11):927-935.
40. Wohl DA, Cohen C, Gallant JE, et al; GS-US-236-0102 Study Team. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr. 2014;65(3):e118-e120.
41. Clumeck N, Molina JM, Henry K, et al; GS-236-0103 Study Team. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr. 2014;65(3):e121-e124.
42. Sax PE, DeJesus E, Mills A, et al; GS-US-236-0102 study team. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012;379(9835):2439-2448.
43. DeJesus E, Rockstroh JK, Henry K, et al; GS-236-0103 Study Team. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet. 2012;379(9835):2429-2438.
44. Landovitz RJ, Ribaudo HJ, Ofotokun I, et al. Efficacy and tolerability of atazanavir, raltegravir, or darunavir with FTC/tenofovir: ACTG 5257 [Abstract 85]. Top Antivir Med. 2014;22(e-1):42-43.
45. Clotet B, Feinberg J, van Lunzen J, et al; on behalf of the ING114915 Study Team. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet. 2014.
46. Elzi L, Erb S, Furrer H, et al Swiss HIV Cohort Study. Choice of initial combination antiretroviral therapy in individuals with HIV infection: determinants and outcomes. Arch Intern Med. 2012;172(17):1313-1321.
47. World Health Organization. The strategic use of antiretrovirals to help end the HIV epidemic. http://www.who.int/hiv/pub/arv/strategic-use/en/. Accessed March 24, 2014.
48. Feinberg J, Clotet B, Khuong MA, et al. Once-daily dolutegravir is superior to darunavir/ritonavir in antiretroviral naive adults: 48 week results from FLAMINGO (ING114915). Presented at: 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 10-13, 2013; Denver, CO. Abstract H-1464a.
49. Zolopa A, Sax PE, DeJesus E, et al; GS-US-236-0102 Study Team. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/ emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/ tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr. 2013;63(1):96-100.
50. Cohen C,Wohl D, Arribas JR, et al.Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults. AIDS. 2014;28(7):989-997.
51. Cohen CJ, Molina JM, Cassetti I, et al; ECHO, THRIVE study groups. Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two phase III randomized trials. AIDS. 2013;27(6):939-950.
52. Cahn P, Andrade-Villanueva J, Arribas JR, et al; on behalf of the GARDEL Study Group. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. Lancet Infect Dis. 2014;14(7):572-580.
53. Raffi F, Babiker AG, Richert L, et al. First-line RAL + DRV/r is non-inferior to TDF/FTC+DRV/r: the NEAT001/ANRS143 randomised trial [Abstract 84LB]. Top Antivir Med. 2014;22(e-1):41-42.
54. D:A:D Study Group; Sabin CA,Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008;371(9622):1417-1426.
55. Strategies for Management of Anti-Retroviral Therapy/INSIGHT; DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS. 2008;22(14):F17-F24.
56. Bedimo RJ,Westfall AO, Drechsler H, Vidiella G, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis. 2011;53(1):84-91.
57. Ding X, Andraca-Carrera E, Cooper C, et al. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J Acquir Immune Defic Syndr. 2012;61(4):441-447.
58. Sabin C, Reiss P, Ryom L, et al. Is there continued evidence for an association between abacavir and myocardial infarction risk? [Abstract 747LB]. Top Antivir Med. 2014;22(e-1):382-383.
59. Sax PE, Tierney C, Collier AC, et al; AIDS Clinical Trials Group Study A5202 Team. Abacavirlamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med. 2009;361(23):2230-2240.
60. Eron Jr J, Rockstroh J, Pozniak A, et al. Abstracts of the Eleventh International Congress on Drug Therapy in HIV Infection 11-15 November 2012, Glasgow, UK. J Int AIDS Soc. 2012;15(suppl 4):3-179.
61. Ryom L, Mocroft A, Kirk O, et al; D:A:D Study Group. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis. 2013;207(9):1359-1369.
62. Rockstroh JK, DeJesus E, Lennox JL, et al STARTMRK Investigators. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr. 2013;63(1):77-85.
63. Walmsley S, Berenguer J, Khuong-Josses MA, et al. Dolutegravir regimen statistically superior to tenofovir/emtricitabine/efavirenz: 96-wk data [Abstract 543]. Top Antivir Med. 2014;22(e-1):261-262.
64. German P, Liu HC, Szwarcberg J, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. J Acquir Immune Defic Syndr. 2012;61(1):32-40.
65. Mollan KR, Smurzynski M, Eron JJ, et al. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med. 2014;161(1):1-10.
66. Napoli A, Coumbis J,Wood J, Soitkar A, Seekins D. Disproportionality analysis of antiretrovirals with suicidality using FDA AERS data [Abstract 761]. Top Antivir Med. 2014;22(e-1):419.
67. Rimsky L, Vingerhoets J, Van Eygen V, et al. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis. J Acquir Immune Defic Syndr. 2012;59(1):39-46.
68. ENCORE1 Study Group. Efficacy of 400 mg efavirenz versus standard 600mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial [published correction appears in Lancet. 2014;383(9927):1464]. Lancet. 2014;383(9927):1474-1482.
69. Soliman EZ, Lundgren JD, Roediger MP, et al INSIGHT SMART Study Group. Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations. AIDS. 2011;25(3):367-377.
70. Rakotondravelo S, Poinsignon Y, Borsa-Lebas F, et al. Complicated atazanavir-associated cholelithiasis: a report of 14 cases. Clin Infect Dis. 2012;55(9):1270-1272.
71. Hamada Y, Nishijima T,Watanabe K, et al. High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy. Clin Infect Dis. 2012;55(9):1262-1269.
72. Mocroft A, Kirk O, Reiss P, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS. 2010;24(11):1667-1678.
73. Daar ES, Tierney C, Fischl MA, et al; AIDS Clinical Trials Group Study A5202 Team. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med. 2011;154(7):445-456.
74. Monforte Ad, Reiss P, Ryom L, et al. Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events. AIDS. 2013;27(3):407-415.
75. Gallant JE, Koenig E, Andrade-Villanueva J, et al. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results. J Infect Dis. 2013;208(1):32-39.
76. Reynes J, Trinh R, Pulido F, et al. Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study. AIDS Res Hum Retroviruses. 2013;29(2):256-265.
77. National Institutes of Health. Comparative trial of maraviroc versus emtricitabine/tenofovir both with darunavir/ritonavir in antiretroviral-naive patients infected with Ccr5 tropic HIV 1 (MODERN). http://clinicaltrials.gov/ ct2/show/NCT01345630?term=maraviroc+once- daily+AND+darunavir+AND+enhanced+AND+ritonavir&rank=1. Accessed March 26, 2014.
78. Antiretroviral Pregnancy Registry; Wilmington North Carolina Registry Coordinating Center. The antiretroviral pregnancy registry: interim report: 1 January 1989 through 31 January 2013. http://www.apregistry.com/forms/interim- report.pdf. Accessed January 6, 2014.
79. Zorrilla CD,Wright R, Osiyemi OO, et al. Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily. HIV Med. 2014;15(1):50-56.
80. Fayet-Mello A, Buclin T, Guignard N, et al Swiss HIV Cohort Study; Mother & Child HIV Cohort Study. Free and total plasma levels of lopinavir during pregnancy, at delivery and postpartum: implications for dosage adjustments in pregnant women. Antivir Ther. 2013;18(2):171-182.
81. Siberry GK, Jacobson DL, Kalkwarf H, et al. Lower newborn bone mineral content associated with maternal use of tenofovir disoproxil fumarate. Top Antivir Med. 2014;22(e-1):34.
82. Cohan D, Natureeba P, Plenty A, et al. Efficacy and safety of LPV/r versus EFV in HIV+ pregnant and breast-feeding Ugandan women. Top Antivir Med. 2014;22(e-1):34-35.
83. Ofotokun I, Ribaudo H, Na L, et al. Darunavir or atazanavir vs raltegravir lipid changes are unlinked to ritonavir exposure: ACTG 5257 [Abstract 746]. Top Antivir Med. 2014;22(e-1):381-382.
84. Morlat P, Vivot A, Vandenhende MA, et al; Groupe D'epidémiologie Clinique du Sida en Aquitaine (Gecsa). Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004-2012. PLoS One. 2013;8(6):e66223.
85. Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir) [package insert]. Foster City, CA: Gilead Sciences Inc; 2012.
86. McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203(12):1791-1801.
87. Brown T, Moser C, Currier J, et al. Bone density changes after antiretroviral initiation with protease inhibitors or raltegravir [Abstract 779LB]. Top Antivir Med. 2014;22(e-1):401.
88. Overton ET, Chan ES, Brown TT, et al. High-dose vitamin D and calcium attenuates bone loss with ART initiation: results from ACTG A5280 [Abstract 133]. Top Antivir Med. 2014;22(e-1):66-67.
89. Luetkemeyer AF, Rosenkranz SL, Lu D, et al; Adult AIDS Clinical Trials Group A5221 Study Team. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. Clin Infect Dis. 2013;57(4):586-593.
90. Blanc FX, Sok T, Laureillard D, et al CAMELIA (ANRS 1295-CIPRA KH001) Study Team. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365(16):1471-1481.
91. Havlir DV, Kendall MA, Ive P, et al; AIDS Clinical Trials Group Study A5221. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011;365(16):1482-1491.
92. Abdool Karim S, Naidoo K, Padayatchi N, et al. Optimal timing of ART during TB therapy: findings of the SAPiT trial. Presented at: 18th Conference on Retroviruses and Opportunistic Infections; February 27-March 2, 2011; Boston, MA.
93. Friedland G, Khoo S, Jack C, Lalloo U. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J Antimicrob Chemother. 2006;58(6):1299-1302. (Pubitemid 44884158)
94. Boulle A, Van Cutsem G, Cohen K, et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA. 2008;300(5):530-539.
95. Naiker S, Conolly C,Weisner L, et al. Pharmacokinetic evaluation of different rifabutin dosing strategies in African TB patients on lopinavir/ritonavir-based ART. Presented at: 18th Conference on Retroviruses and Opportunistic Infections; February 27-March 2, 2011; Boston, MA.
96. Boulanger C, Hollender E, Farrell K, et al. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin Infect Dis. 2009;49(9):1305-1311.
97. Jenny-Avital ER, Joseph K. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy. Clin Infect Dis. 2009;48(10):1471-1474.
98. Grinsztejn B, De Castro N, Arnold V, et al; ANRS 12 180 Reflate TB study group. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial. Lancet Infect Dis. 2014;14(6):459-467.
99. Dooley KE, Sayre P, Borland J, et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr. 2013;62(1):21-27.
100. Centers for Disease Control and Prevention (CDC). Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep. 2011;60(48):1650-1653.
101. Sterling T, Benson C, Scott N, et al. Three months of weekly rifapentine + INH for M. tuberculosis infection in HIV-infected persons [Abstract 817]. Top Antivir Med. 2014;22(e-1):425.
102. Podany AT, Bao Y, Chaisson RE, et al. Efavirenz pharmacokinetics in HIV+ persons receiving rifapentine and isoniazid for TB prevention [Abstract 105]. Top Antivir Med. 2014;22(e-1):54-55.
103. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009;360(23):2397-2405.
104. Karageorgopoulos DE, El-Sherif O, Bhagani S, Khoo SH. Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection. Curr Opin Infect Dis. 2014;27(1):36-45.
105. AASLD; IDSA IAS-USA. Recommendations for testing, managing, and treating hepatitis C. http://hcvguidelines.org/. Accessed May 20, 2014.
106. Liverpool HIV and Hepatitis Pharmacology Group. Drug interaction chart. http://www.hiv-druginteractions.org/. Accessed March 25, 2014.
107. Sax PE. Editorial commentary: can we break the habit of routine CD4 monitoring in HIV care? Clin Infect Dis. 2013;56(9):1344-1346.
108. Bonner K, Mezochow A, Roberts T, Ford N, Cohn J. Viral load monitoring as a tool to reinforce adherence: a systematic review. J Acquir Immune Defic Syndr. 2013;64(1):74-78.
109. Gale HB, Gitterman SR, Hoffman HJ, et al. Is frequent CD4+ T-lymphocyte count monitoring necessary for persons with counts >=300 cells/μL and HIV-1 suppression? Clin Infect Dis. 2013;56(9):1340-1343.
110. Whitlock GG, Ahmed N, Benn P, Edwards S, Waters L. Stop routine CD4 monitoring in HIV-infected patients with fully suppressed virus and CD4 >=350 cells/ml. Clin Infect Dis. 2013;57(2):327-328.
111. Hyle EP, Sax PE,Walensky RP. Potential savings by reduced CD4 monitoring in stable patients with HIV receiving antiretroviral therapy. JAMA Intern Med. 2013;173(18):1746-1748.
112. Swenson LC, Cobb B, Geretti AM, et al International Viral Load Assay Collaboration. Comparative performances of HIV-1 RNA load assays at low viral load levels: results of an international collaboration. J Clin Microbiol. 2014;52(2):517-523.
113. Ruelle J, Debaisieux L, Vancutsem E, et al. HIV-1 low-level viraemia assessed with 3 commercial real-time PCR assays show high variability. BMC Infect Dis. 2012;12:100.
114. Li JZ, Gallien S, Ribaudo H, Heisey A, Bangsberg DR, Kuritzkes DR. Incomplete adherence to antiretroviral therapy is associated with higher levels of residual HIV-1 viremia. AIDS. 2014;28(2):181-186.
115. Pugliese P, Delpierre C, Cuzin L, et al Dat AIDS Study Group. An undetectable polymerase chain reaction signal in routine HIV plasma viral load monitoring is associated with better virological outcomes in patients receiving highly active antiretroviral therapy. HIV Med. 2013;14(8):509-515.
116. Maggiolo F, Callegaro A, Cologni G, et al. Ultrasensitive assessment of residual low-level HIV viremia in HAART-treated patients and risk of virological failure. J Acquir Immune Defic Syndr. 2012;60(5):473-482.
117. Charpentier C, Landman R, Laouénan C, et al. Persistent low-level HIV-1 RNA between 20 and 50 copies/mL in antiretroviral-treated patients: associated factors and virological outcome. J Antimicrob Chemother. 2012;67(9):2231-2235.
118. Laprise C, de Pokomandy A, Baril JG, Dufresne S, Trottier H. Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation. Clin Infect Dis. 2013;57(10):1489-1496.
119. Vandenhende MA, Ingle S, May M, et al. Impact of low-level viremia on clinical and virological outcomes in treated HIV infected patients [Abstract 1014]. Top Antivir Med. 2014;22(e-1):535-536.
120. Li JZ, Gallien S, Do TD, et al. Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia. Antimicrob Agents Chemother. 2012;56(11):5998-6000.
121. Swenson LC, Min JE,Woods CK, et al. HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure. AIDS. 2014.
122. Delaugerre C, Gallien S, Flandre P, et al. Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients. PLoS One. 2012;7(5):e36673.
123. Gonzalez-Serna A, Min JE, Woods C, et al. Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals. Clin Infect Dis. 2014;58(8):1165-1173.
124. Hirsch MS, Günthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis. 2008;47(2):266-285.
125. Wittkop L, Günthard HF, de Wolf F, et al; EuroCoord-CHAIN study group. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 2011;11(5):363-371.
126. Schoenenberger JA, Aragones AM, Cano SM, et al. The advantages of therapeutic drug monitoring in patients receiving antiretroviral treatment and experiencing medication-related problems. Ther Drug Monit. 2013;35(1):71-77.
127. Colbers A, Greupink R, Burger D. Pharmacological considerations on the use of antiretrovirals in pregnancy. Curr Opin Infect Dis. 2013;26(6):575-588.
128. Rakhmanina N, Phelps BR. Pharmacotherapy of pediatric HIV infection. Pediatr Clin North Am. 2012;59(5):1093-1115.
129. Charania MR, Marshall KJ, Lyles CM, et al HIV/AIDS Prevention Research Synthesis (PRS) Team. Identification of evidence-based interventions for promoting HIV medication adherence: findings from a systematic review of US-based studies, 1996-2011. AIDS Behav. 2014;18(4):646-660.
130. Taiwo B, Yanik EL, Napravnik S, et al CFAR Network of Integrated Clinical Systems (CNICS) Cohort Study. Evidence for risk stratification when monitoring for toxicities following initiation of combination antiretroviral therapy. AIDS. 2013;27(10):1593-1602.
131. Buscher A, Mugavero M,Westfall AO, et al. The association of clinical follow-up intervals in HIV-infected persons with viral suppression on subsequent viral suppression. AIDS Patient Care STDS. 2013;27(8):459-466.
132. Miller V, Nwokike J, Stergachis A. Pharmacovigilance and global HIV/AIDS. Curr Opin HIV AIDS. 2012;7(4):299-304.
133. Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;58(1):e1-e34.
134. Kulkarni R, Abram ME, Rhee MS, et al. Week 144 resistance analyses of the phase 3 EVG/COBI/FTC/TDF studies. Top Antivir Med. 2014;22(e1):288.
135. Hill A, McBride A, Sawyer AW, Clumeck N, Gupta RK. Resistance at virological failure using boosted protease inhibitors versus nonnucleoside reverse transcriptase inhibitors as first-line antiretroviral therapy - implications for sustained efficacy of ART in resource-limited settings. J Infect Dis. 2013;207(suppl 2):S78-S84.
136. Scherrer AU, Böni J, Yerly S, et al; Swiss HIV Cohort Study (SHCS). Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens. PLoS One. 2012;7(11):e50307.
137. Ajose O, Mookerjee S, Mills EJ, Boulle A, Ford N. Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. AIDS. 2012;26(8):929-938.
138. Boyd MA, Kumarasamy N, Moore CL, et al SECOND-LINE Study Group. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study. Lancet. 2013;381(9883):2091-2099.
139. Paton N, Kityo C, Hoppe A, et al. A pragmatic randomised controlled strategy trial of three second-line treatment options for use in public health rollout programme settings: the Europe-Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial. Presented at: 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Kuala Lumpur, Malaysia; June 30-July 3, 2013. Abstract WELBB02.
140. Sension M, Cahn P, Domingo P, et al. Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial. HIV Med. 2013;14(7):437-444.
141. Hicks CB, Cahn P, Cooper DA, et al; RESIST investigator group. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet. 2006;368(9534):466-475. (Pubitemid 44142769)
142. Trottier B, Di Perri G, Madruga JV, et al. Impact of the background regimen on virologic response to etravirine: pooled 48-week analysis of DUET-1 and -2. HIV Clin Trials. 2010;11(4):175-185.
143. Katlama C, Haubrich R, Lalezari J, et al; DUET-1, DUET-2 study groups. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS. 2009;23(17):2289-2300.
144. Vingerhoets J, Tambuyzer L, Azijn H, et al. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled phase III clinical studies. AIDS. 2010;24(4):503-514.
145. Zolopa AR, Berger DS, Lampiris H, et al. Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. J Infect Dis. 2010;201(6):814-822.
146. Molina JM, Lamarca A, Andrade-Villanueva J, et al Study 145 Team. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis. 2012;12(1):27-35.
147. Cahn P, Pozniak AL, Mingrone H, et al Extended SAILING Study Team. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013;382(9893):700-708.
148. Eron JJ, Clotet B, Durant J, et al VIKING Study Group. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis. 2013;207(5):740-748.
149. Castagna A, Maggiolo F, Penco G, et al; for the VIKING-3 Study Group. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/ or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study [published ahead of print February 23, 2014]. J Infect Dis. doi:10.1093/infdis/ jiu051.
150. Hardy WD, Gulick RM, Mayer H, et al. Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2. J Acquir Immune Defic Syndr. 2010;55(5):558-564.
151. Tashima K, Smeaton L, Andrade A, et al. Omitting NRTI from ARV regimens is not inferior to adding NRTI in treatment-experienced HIV+ subjects failing a protease inhibitor regimen: the ACTG OPTIONS study. Presented at: 20th Conference on Retroviruses and Opportunistic Infections; March 3-6, 2013; Atlanta, GA.
152. Wohl DA, Bhatti L, Small CB, et al. Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial. PLoS One. 2014;9(5):e96187.
153. Masiá M, Martínez E, Padilla S, Gatell JM, Gutiérrez F. Endothelial function in HIV-infected patients switching from a boosted protease inhibitor-based regimen to raltegravir: a substudy of the SPIRAL study. J Antimicrob Chemother. 2013;68(2):409-413.
154. Curran A, Martinez E, Saumoy M, et al. Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy. AIDS. 2012;26(4):475-481.
155. Martínez E, D'Albuquerque PM, Llibre JM, et al; SPIRAL Trial Group. Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir. AIDS. 2012;26(18):2315-2326.
156. Eron JJ, Young B, Cooper DA, et al; SWITCHMRK 1 and 2 Investigators. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet. 2010;375(9712):396-407.
157. Mills AM, Cohen C, Dejesus E, et al. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens. HIV Clin Trials. 2013;14(5):216-223.
158. Mills A, Crofoot G, Ortiz R, et al. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data. HIV Clin Trials. 2014;15(2):51-56.
159. Arribas JR, Pialoux G, Di Perri G, et al. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial. Lancet Infect Dis. 2014;14(7):581-589.
160. Pozniak A, Markowitz M, Mills A, et al. Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial. Lancet Infect Dis. 2014;14(7):590-599.
161. Palella FJ Jr, Fisher M, Tebas P, et al. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants. AIDS. 2014;28(3):335-344.
162. Ghosn J, Slama L, Chermak A, et al RADAR Study Group. Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1. J Med Virol. 2013;85(1):8-15.
163. Reina E, San Miguel R, Larrea N, Garcia P, Napal V. Potential for simplification of HIV treatment with boosted protease inhibitor monotherapy. Int J Clin Pharm. 2012;34(6):911-916.
164. Guiguet M, Ghosn J, Duvivier C, et al; FHDH-ANRS CO4. Boosted protease inhibitor monotherapy as a maintenance strategy: an observational study. AIDS. 2012;26(18):2345-2350.
165. Lambert-Niclot S, Flandre P, Valantin MA, et al. Factors associated with virological failure in HIV-1-infected patients receiving darunavir/ritonavir monotherapy. J Infect Dis. 2011;204(8):1211-1216.
166. Mathis S, Khanlari B, Pulido F, et al. Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: ameta-analysis. PLoS One. 2011;6(7):e22003.
167. Paton N, Stohr W, Arenas-Pinto A, Dunn D. the PIVOT Trial Group. Randomised controlled trial of a PI monotherapy switch strategy for long-term HIV management [Abstract 550LB]. Top Antivir Med. 2014;22(e-1):266-267.
168. Gutmann C, Cusini A, Günthard HF, et al; Swiss HIV Cohort Study (SHCS). Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS. 2010;24(15):2347-2354.
169. UNAIDS. Epidemiology publications. http://www.unaids.org/en/dataanalysis/ knowyourepidemic/epidemiologypublications/. Accessed March 25, 2014.
170. Avila D, Althoff KN, Mugglin C, et al; IeDEA and ART Cohort Collaborations. Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr. 2014;65(1):e8-e16.
171. Volz EM, Ionides E, Romero-Severson EO, Brandt MG, Mokotoff E, Koopman JS. HIV-1 transmission during early infection in men who have sex with men: a phylodynamic analysis. PLoS Med. 2013;10(12):e1001568.
172. Brenner BG, Roger M, Stephens D, et al Montreal PHI Cohort Study Group. Transmission clustering drives the onward spread of the HIV epidemic among men who have sex with men in Quebec. J Infect Dis. 2011;204(7):1115-1119.
173. Drescher SM, von Wyl V, Yang WL, et al Swiss HIV Cohort Study. Treatment-naive individuals are the major source of transmitted HIV-1 drug resistance in men who have sex with men in the Swiss HIV Cohort Study. Clin Infect Dis. 2014;58(2):285-294.